A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

• Status: Completed
• Trial end date: 2016-04-22
• Target enrollment: 0
• Participant gender: All

Summary

This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder (MDD).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Desvenlafaxine Succinate

Criteria

Inclusion Criteria:

• Completed study B2061032 and who in the investigator's opinion, would benefit from long term treatment with DVS SR

• Willingness and ability to comply with scheduled visits, treatment plan, and procedures

Exclusion Criteria:

• Requires precaution against suicide

• Not in generally healthy medical condition

• Poor compliance with study drug or study procedures during participation in study B2061032